Sun Pharmaceutical Industries Limited has announced the launch of its semaglutide injection in India under the brand names Noveltreat and Sematrinity. The introduction expands access to therapies for chronic weight management and type 2 diabetes, offering multiple dosage strengths and more affordable weekly treatment options.
Noveltreat has been introduced for chronic weight management in adults and is prescribed alongside a reduced-calorie diet and increased physical activity. It is available in five strengths: 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL. Sematrinity is indicated for adults with inadequately controlled type 2 diabetes and is offered in two strengths: 2 mg/1.5 mL and 4 mg/3 mL.
The therapies are positioned to improve affordability, with weekly treatment costs ranging from approximately ₹900 to ₹2,000 for Noveltreat and ₹750 to ₹1,300 for Sematrinity, depending on dosage. The pricing aims to broaden access to semaglutide-based treatment options for patients across India.
Commenting on the launch, Managing Director Kirti Ganorkar stated that the company’s focus is to expand access to high-quality therapies while supporting patients throughout their treatment journey. In addition to the product rollout, Sun Pharma is introducing a patient support program designed to assist individuals with guidance, adherence, and ongoing care.
Both products are delivered through pre-filled pen devices designed to improve ease of use and dosing accuracy. Noveltreat features a concealed needle system intended to reduce injection-related anxiety and enhance safety during administration. Sematrinity is supplied in a multi-dose pen format with a dial mechanism that allows flexible and precise dosing. The devices are developed by global pharmaceutical technology providers and manufactured in Europe.
Semaglutide belongs to the GLP-1 receptor agonist class, widely used in the treatment of type 2 diabetes and obesity. These therapies are associated with improved glycaemic control and have demonstrated benefits in reducing cardiovascular and renal risks.
The launch comes amid rising health concerns in India. National survey data indicates that nearly one in four individuals aged 15 to 49 is overweight or obese, while recent estimates suggest over 100 million people are living with diabetes. A significant proportion of patients do not achieve recommended blood sugar targets, highlighting the need for effective treatment options and sustained disease management.
Sun Pharma is a global specialty generics company with a presence across specialty, generics, and consumer healthcare. It is the largest pharmaceutical company in India and among the leading generics players in the United States and emerging markets. The company’s specialty portfolio includes dermatology, ophthalmology, and onco-dermatology products, and its medicines are supplied across more than 100 countries through vertically integrated manufacturing operations spanning six continents.
